Multimodal Treatment Strategy for Cancer Cachexia

NCT ID: NCT00625742

Last Updated: 2016-02-12

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-02-29

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary aim of this proposal is to present a novel, multimodal treatment strategy for increasing lean body mass in individuals with cancer who experience cachexia between baseline and day 29 (+/- 3 days). The strategy includes graded resistance training and aerobic exercise, targeted nutrient supplementation and pharmacologic intervention (melatonin).

We postulate that this strategy, together with the simultaneous management of symptoms that decrease appetite (e.g. depression, pain, and nausea), will also accomplish our secondary objectives of improving clinical outcomes such as strength and function between baseline and day 29 (+/- 3 days).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Study Drugs:

Melatonin is a hormone that helps reduce inflammation and poor food absorption caused by cancer. It may also enhance the effects of ibuprofen.

Juven is a nutritional supplement that is designed to help build muscle and slow muscle breakdown.

Screening Tests:

Before you can start treatment on this study, you will have "screening tests" to help the doctor decide if you are eligible to take part in this study. The following tests will be performed:

* Blood (1 to 2 tablespoons) will be drawn for routine tests. This routine blood draw will include a pregnancy test for women who are able to have children. To be eligible to take part in this study, the pregnancy test must be negative.
* Additional blood (1 tablespoon) will be drawn to check your thyroid function and the levels of two B vitamins, if these have not been checked within the past 3 months.
* You will have a physical exam, including measurement of vital signs (blood pressure, heart rate, temperature, and breathing rate).
* You will have an electrocardiogram (ECG -- a test that measures the electrical activity of the heart).
* Your resting energy expenditure (energy used at rest) will be measured. with a calorie-measuring device. For this test, you will breathe in and out through your mouth for about 10 minutes to allow a calorie-measuring device to measure the oxygen your body uses, and from this it calculates how much energy your body uses at rest.
* You will be asked to fill out a questionnaire to rate your overall physical well-being, another questionnaire to rate your level of fatigue, and a third questionnaire to rate your experiences with 10 common symptoms in the past 24 hours (pain, fatigue, nausea, depression, anxiety, drowsiness, shortness of breath, changes in appetite, sleep difficulty, and feeling of well being). In total, these questionnaires will take about 30 minutes to complete.
* You will complete a diary entry that lists all of the food and drinks you have had in the last 3 days. It should take about 10 minutes to complete.
* Your strength and stamina will be evaluated. This is measured by hand-grip and pinch strength tests that are done with both hands. These tests will see how hard you can grip a device with your hand and pinch the pads of another device called a pinch gauge. These tests will be done 3 times and your best scores will be used. Your strength and stamina will also be checked using the Get-Up-and-Go test and the 6-minute walk test. The Get-Up-and-Go test measures how long it takes to get up from sitting in a chair that has arms, walking 10 feet, turning around and walking back to the chair, and sitting down. The 6-minute walk test will measure the distance you can walk in 6 minutes on a 100-foot loop. You will walk 50 feet and then turn and walk back to the beginning. You will do this at a walking speed that feels comfortable and for as many times as you can in 6 minutes.
* Blood (1 to 2 tablespoons) will be drawn to check for markers of inflammation and nutrition status.

Study Drug Administration:

You will take one (1) 20mg capsule of melatonin every night. It can be taken with or without food. It should be taken with 8 ounces (1 cup) of water.

You will drink 90 calories of Juven, twice a day. Juven is a powder supplement that is mixed into 8 ounces of water. It is available in orange or grape flavors.

You will also be instructed to increase your daily calorie intake by at least 1,000 calories. To assist you in doing so, dietary advice will be given to you by a nurse or physician.

Exercise Training:

You will complete 2 exercise training sessions a week. The sessions will combine resistance and graded aerobic training.

Resistance training (with Thera-bands) is designed to increase the muscle-building effects of a hormone called testosterone. Thera-bands are rubber bands that you can hold or put around your feet to provide resistance to your muscles when you bend and flex your arms and legs.

You will be instructed in how to do 3 upper-body exercises (chest press, shoulder press, and arm pull down) and 3 lower-body exercises (leg press, leg extension, and leg flexion).

At your first visit, a physician will educate you to make sure that all exercises are done correctly.

Each repetition will take 12 seconds to complete (6 seconds to bend, then 6 seconds to straighten your arm or leg). When 6 repetitions are completed, the next week's set will be increased by 1 repetition.

Graded aerobic exercise is a walking/running program that may help you exercise longer.

Graded aerobic exercise involves walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate. There will be a 3-minute warm-up and a 3-minute cool-down before and after this exercise.

During your first visit, you will be shown how to monitor your heart rate and how to exercise at 70-80% of your maximum heart rate.

You will add 1 minute to your aerobic exercise at the start of each week.

You will receive your own customized aerobic and resistance exercise program based on your range of motion and risk for falls, which will be evaluated by the study staff.

If you experience chest pain, have a temperature over 100.4 °F, have a platelet count of lower than a certain level, have fresh bruises, or shortness of breath at rest, you will be advised to stop exercising until these are relieved.

Evaluations:

While on study, within 3 days of the days listed below, the following measurements will be monitored:

* Your lean body mass and weight will be checked at Days 15 and 29 using the Tanita TBF-310 body composition analyzer/scale. For measurements with the Tanita TBF 310, you will be asked to wear light clothes and to take off your shoes and socks when being weighed. You will stand on a special scale that will send an extremely low-energy, high-frequency electrical signal from one foot to your other foot. You should not be able to feel this at all.
* Your muscle mass (mid-arm muscle area) will be measured with a special tape.
* The thickness of a skin fold on your triceps (back of your upper arm) will be measured 3 times using skin fold calipers. Calipers are a gentle clamp-like device that is used on the outside of your body to measure skin thickness.
* At Day 29, your resting energy expenditure will be measured.
* On Days 15 and 29 of the study cycle, you will complete the same 3 questionnaires as at screening.
* Your caloric intake will be measured on Days 15 and 29.
* Your strength and stamina will be evaluated on Days 15 and 29.
* On Day 29, blood (1 to 2 tablespoons) will be drawn to check for markers of inflammation and nutrition.
* Blood (about 1 to 2 tablespoons) will be drawn for routine tests every 15 days while you are on-study. You will also have a fecal occult blood test at this time.

Length of Study:

You will be on study for 29 days (1 cycle).

This is an investigational study. Melatonin and Juven are commercially available nutritional supplements and are exempt from FDA approval. However, in patients with cancer and cachexia, the study treatment (resistance training, aerobic exercise, and the use of Juven, and melatonin) is considered experimental. At this time, it is only being used in research.

Up to 40 patients will be enrolled on this study. Up to 30 patients will be enrolled at M.D. Anderson, and 10 will be enrolled at the University of Alabama-Birmingham.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Cancer Cachexia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Multimodal Treatment Strategy

Exercise Program + Pharmacologic Intervention (Melatonin + Atenolol + Ibuprofen) + Nutritional Supplementation (Juven) - Resistance training sessions twice weekly using Thera-bands. Walking or running for 3-4 minutes at 70-80% of maximum predicted heart rate. Melatonin 20 mg by mouth (PO) Daily. 90 calories of Juven, twice a day.

Group Type EXPERIMENTAL

Atenolol

Intervention Type DRUG

Atenolol will only be taken if there's evidence of increased sympathetic activity (resting heart rate \>110 beats/min) or resting energy expenditure (REE) \> 110% of predicted.

Ibuprofen

Intervention Type DRUG

Ibuprofen 1200mg/day in three divided doses.

Graded Resistance Training

Intervention Type BEHAVIORAL

Resistance training sessions twice weekly using Thera-bands.

Aerobic Exercise

Intervention Type BEHAVIORAL

Walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate.

Melatonin

Intervention Type DRUG

20 mg by mouth (PO) Daily

Juven

Intervention Type DIETARY_SUPPLEMENT

90 calories of Juven, twice a day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atenolol

Atenolol will only be taken if there's evidence of increased sympathetic activity (resting heart rate \>110 beats/min) or resting energy expenditure (REE) \> 110% of predicted.

Intervention Type DRUG

Ibuprofen

Ibuprofen 1200mg/day in three divided doses.

Intervention Type DRUG

Graded Resistance Training

Resistance training sessions twice weekly using Thera-bands.

Intervention Type BEHAVIORAL

Aerobic Exercise

Walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate.

Intervention Type BEHAVIORAL

Melatonin

20 mg by mouth (PO) Daily

Intervention Type DRUG

Juven

90 calories of Juven, twice a day.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Are referred to the Cachexia Clinic with involuntary weight loss of \>5% of their premorbid weight within the previous 6 months.
2. Are 18 years of age or older
3. Have a Karnofsky performance score of 60 or higher.
4. Can maintain oral food intake during the study
5. Can understand the study procedures and can sign an informed consent form.
6. Are not currently taking melatonin.
7. Are taking megestrol acetate and continue to lose weight despite at least 2 weeks of therapy.
8. Have a calculated creatinine clearance of \>/= 60 cc/min.

Exclusion Criteria

1. Have dementia or delirium (as determined by the palliative care specialist) at study entry.
2. Are pregnant
3. Have been taking corticosteroids for longer than 48 hours.
4. Have pulmonary edema, ascites or pitting edema on clinical examination.
5. Are unable to walk.
6. Have a history of serious adverse gastrointestinal events (i.e., bleeding or perforation),history of a coagulopathy or current anti-coagulant use.
7. Have an ALT/AST\>3x upper limit of normal.
8. Patients on methotrexate.
9. Patients taking melatonin receptor agonists (such as Rozerem® \[ramelteon\]).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

M.D. Anderson Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rony Dev, DO

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UT MD Anderson Cancer Center

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://www.mdanderson.org

MD Anderson Cancer Center

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2012-01744

Identifier Type: REGISTRY

Identifier Source: secondary_id

2006-0739

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of AL8326 in Healthy Subjects
NCT07132957 COMPLETED PHASE1